In the article cited above, the duality of interest disclosures were inadvertently omitted. The text below replaces the previous “Funding” and “Duality of Interest” sections:
Funding and Duality of Interest. This study was partially funded by an unrestricted grant from Medtronic. A.A. reports receiving grants from Medtronic. D.E.A. reports receiving grants from the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK-105960) and the Patient-Centered Outcomes Research Institute and receiving nonfinancial support from the International Federation for the Surgery of Obesity and Metabolic Disorders, Latin America Chapter. S.A.B. reports receiving grants from Medtronic and GI Windows. P.R.S. reports receiving grants from Medtronic, Ethicon, and Pacira and receiving personal fees from Medtronic, GI Dynamics, W.L. Gore and Associates, Becton Dickinson Surgical, and Global Academy for Medical Education. S.E.N. reports receiving a grant from Medtronic for the current study and receiving research support from Amgen, AbbVie, AstraZeneca, Cerenis, Eli Lilly, Esperion Therapeutics, Novo Nordisk, The Medicines Company, Orexigen, Pfizer, and Takeda and consulting for a number of pharmaceutical companies without financial compensation (all honoraria, consulting fees, or other payments from any for-profit entity are paid directly to charity, so neither income nor any tax deduction is received). M.W.K. reports receiving grants from Medtronic and Novo Nordisk. No other potential conflicts of interest relevant to this article were reported.
Medtronic had no role in the design and conduct of the study; collection, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
The online version of the article (https://doi.org/10.2337/dc19-2057) has been updated with this information.